Stocks & Indices Unverified First seen 2026-10-09 13:48 UTC

Teva stock surges after FDA approves once-monthly schizophrenia drug

Investor's Business Daily reported that Teva stock surged Friday after the FDA approved its schizophrenia drug, described as a once-monthly injectable treatment. The post also stated Teva was already up 26% this year.

Why “Unverified”

Reported by Investor's Business Daily alone, with no second source or primary confirmation yet

1 independent source group across 1 post · evidence score 52/100. How labels work

What the sources claim

Teva stock surged Friday after the FDA approved its schizophrenia drug.

“Teva stock surged Friday after the FDA approved its schizophrenia drug”
Investor's Business Daily
The approved drug is a once-monthly injectable treatment for schizophrenia.

“a once-monthly injectable treatment for the disease”
Investor's Business Daily
Teva was already up 26% this year.

“Already Up 26% This Year”
Investor's Business Daily

Sources

Investor's Business Daily newswire 2026-10-09 13:48 UTC
Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval

More in Stocks & Indices

All Stocks & Indices stories →

Summary and claims extracted by AI with prompt analyze-story@4 on 2026-10-12 06:40 UTC. Labels are computed from the sources, not by the model.